Summary
The pharmacokinetics of vinpocetine (Cavinton®) and of its main metabolite apovincaminic acid (AVA), has been studied in 5 healthy male volunteers after the administration of 3 × 5 and 3 × 10 daily doses of vinpocetine for seven days. The pharmacokinetic curves of both vinpocetine and AVA have been determined prior to the chronic administration and on the last day of the treatment, whereas between the 2nd and 6th days, concentration was measured once daily. On the basis of these pharmacokinetic studies it can be concluded that both vinpocetine and AVA show linear pharmacokinetics at the doses used and that there is no accumulation or autoinduction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hadjiev D., Yancheva S. (1976): Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneimittelforsch., 26, 1947–1950.
Szobor A., Klein M., (1976): Ethyl apovincaminate therapy in neurovascular disease. Arzneimittelforsch., 26, 1984–1989.
Biró K., Kárpáti E., Szporny L. (1976): Protective activity of ethyl apovincaminate on ischaemic anoxia of brain. Arzneimittelforsch., 26, 1918–1920.
Bencsath P., Debreczeni L., Takfcs L. (1976): Effect of ethyl apovincaminate on cerebral circulation of dogs under normal conditions and in arterial hypoxia. Arzneimittelforsch., 26, 1920–1923.
Kárpáti E., Szpomy L. (1976): General and cerebral haemodynamic activity of ethyl apovincaminate. Arzneimittelforsch., 26,1908–1912.
Vereczkey L., Czira G., Tamás J., Szentirmai Zs., Botár Z., Szporny L. (1979): Pharmacokinetics of vinpocetine in humans. Arzneimittelforsch., 29, 937–960.
Miskolczi P., Vereczkey L., Szalay L., Göndöcs Cs. (1987): Effect of age on the pharmacokinetics of vinpocetine and apovincaminic acid. Eur. J. Clin. Pharmacol., 33, 185–189.
Polgár M, Vereczkey L., Nyáry I. (1985): Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid in plasma and cerebrospinal fluid after intravenous infusioa Effect of the drug on the cerebral blood flow. J. Pharm. Biomed. Anal., 3, 131–139.
Miskolczi P., Vereczkey L., Szporny L., et al. (1985): The pharmacokinetics of vinpocetine in patients with impaired liver function. Proc. 4th Congr. Hung. Pharmacol. Sec. Budapest, 2, 413–417.
Miskolczi P., Vereczkey L., Szalay L., Göndöcs Cs. (1984): Pharmacokinetics of vinpocetine and apovincaminic acid in patients with impaired renal function. Eur. J. Drug Metab. Pharmacokinet, 9, 165–175.
Polgar M., Vereczkey L. (1983): Gas-liquid chromatographic method for quantification of vinpocetine in biological fluids. In: Frigerio A. (ed). Chromatography in Biochemistry, Medicine and Environmental Research Vol 1. Amsterdam, Elsevier, pp. 77–81.
Kozma M., Pudleiner P., Vereczkey L. (1982): Determination of apovinacaminic acid in biological samples by HPLC. J. Chromatogr., 241, 177–182.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miskolczi, P., Kozma, K., Polgár, M. et al. Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur. J. Drug Metab. Pharmacokinet. 15, 1–5 (1990). https://doi.org/10.1007/BF03190120
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190120